Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 13/20 | 0.51 |
| ▸ | EGFR | P00533 | 7/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4068059 | 0.93 | RIPK1 (0.55) | RIPK1CSF1REGFRBTKTBK1 | |
| SCHEMBL4063817 | 0.88 | RIPK1 (0.59) | RIPK1CSF1REGFRBTKTBK1 | |
| SCHEMBL4064647 | 0.82 | CSF1R (0.61) | CSF1REGFRPRMT5 | |
| SCHEMBL4068055 | 0.81 | RIPK1 (0.55) | RIPK1CSF1REGFRBTKTBK1 | |
| SCHEMBL4472467 | 0.81 | RIPK1 (0.52) | RIPK1EGFRBTKTBK1ALK | |
| SCHEMBL4068943 | 0.80 | RIPK1 (0.59) | RIPK1BTKTBK1ALK | |
| SCHEMBL13604150 | 0.80 | RIPK1 (0.61) | RIPK1BTKTBK1ALKKIT | |
| SCHEMBL4467935 | 0.80 | RIPK1 (0.64) | RIPK1BTKTBK1ALKKIT | |
| SCHEMBL5794775 | 0.80 | KDR (0.51) | RIPK1CSF1REGFRALK | |
| SCHEMBL4065929 | 0.79 | RIPK1 (0.60) | RIPK1EGFRBTKTBK1ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625894-B2 | Pyrrolo[2,3-d]Pyrimidines as Protein Tyrosine Kinase Inhibitors | NOVARTIS AG (CH) | 2009-12-01 | — | — | US | disclosed |
| US-7625894-B2 | Pyrrolo[2,3-d]Pyrimidines as Protein Tyrosine Kinase Inhibitors | NOVARTIS AG (CH) | 2009-12-01 | — | — | US | disclosed |
| US-20070135460-A1 | 7H-pyrrolopyrimidine derivatives | CARAVATTI GIORGIO | 2007-06-14 | — | — | US | disclosed |
| US-20070135460-A1 | 7H-pyrrolopyrimidine derivatives | CARAVATTI GIORGIO | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135460-A1 | 7H-pyrrolopyrimidine derivatives | DPYD, TYMP, DHPS | RIPK1 3871/4885CSF1R 3432/4885EGFR 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.